Atara Biotherapeutics Financials
ATRA Stock | USD 11.31 1.21 11.98% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.68 | 0.7162 |
|
|
Investors should never underestimate Atara Biotherapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Atara Biotherapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Atara Biotherapeutics.
Net Income |
|
Atara | Select Account or Indicator |
Understanding current and past Atara Biotherapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atara Biotherapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Atara Biotherapeutics' assets may result in an increase in income on the income statement.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.
Atara Biotherapeutics Stock Summary
Atara Biotherapeutics competes with Fate Therapeutics, Sana Biotechnology, Caribou Biosciences, Arcus Biosciences, and Heron Therapeuti. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0465131078 |
CUSIP | 046513107 046513206 |
Location | California; U.S.A |
Business Address | 2380 Conejo Spectrum |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.atarabio.com |
Phone | 805 623 4211 |
Currency | USD - US Dollar |
Atara Biotherapeutics Key Financial Ratios
Return On Equity | -20.15 | ||||
Profit Margin | (2.90) % | ||||
Operating Margin | (0.62) % | ||||
Price To Sales | 0.92 X | ||||
Revenue | 8.57 M |
Atara Biotherapeutics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 342.9M | 588.1M | 468.1M | 376.4M | 165.5M | 302.7M | |
Other Current Liab | 5.7M | 40.3M | 44.9M | 50.4M | 48.5M | 51.0M | |
Other Liab | 1.0M | 29.7M | 57.2M | 109.2M | 125.5M | 131.8M | |
Net Debt | (60.2M) | (187.4M) | (80.6M) | (21.2M) | 31.9M | 33.5M | |
Retained Earnings | (818.0M) | (1.1B) | (1.5B) | (1.7B) | (2.0B) | (1.9B) | |
Accounts Payable | 8.0M | 7.1M | 17.4M | 6.9M | 3.7M | 6.1M | |
Cash | 74.3M | 200.4M | 106.1M | 92.9M | 26.0M | 24.7M | |
Other Assets | 1.8M | 14.3M | 3.6M | 7.0M | 1.0 | 0.95 | |
Other Current Assets | 13.9M | 21.4M | 12.6M | 10.3M | 6.2M | 8.6M | |
Total Liab | 52.2M | 125.8M | 188.5M | 249.8M | 264.7M | 278.0M | |
Total Current Assets | 273.0M | 523.3M | 384.6M | 295.1M | 101.9M | 96.8M | |
Common Stock | 6K | 8K | 9K | 10K | 11K | 5.7K | |
Net Tangible Assets | 290.8M | 462.3M | 279.6M | 126.6M | 145.6M | 287.0M | |
Capital Surpluse | 1.1B | 1.6B | 1.7B | 1.8B | 2.1B | 1.1B | |
Net Invested Capital | 290.8M | 462.3M | 279.6M | 126.6M | (99.2M) | (94.3M) | |
Net Working Capital | 236.2M | 440.4M | 278.8M | 216.2M | (40.4M) | (38.3M) | |
Short Term Debt | 1.6M | 2.0M | 2.8M | 13.6M | 12.2M | 12.8M | |
Capital Stock | 6K | 8K | 9K | 10K | 11K | 9.0K |
Atara Biotherapeutics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Operating Income | (295.7M) | (309.1M) | (340.5M) | (280.5M) | (269.3M) | (282.7M) | |
Ebit | (295.7M) | (309.1M) | (340.5M) | (345.3M) | (269.3M) | (282.7M) | |
Research Development | 216.1M | 244.7M | 282.0M | 272.5M | 219.2M | 147.7M | |
Ebitda | (288.6M) | (300.7M) | (331.1M) | (330.8M) | (264.4M) | (277.7M) | |
Income Before Tax | (291.0M) | (306.6M) | (340.1M) | (228.3M) | (276.1M) | (262.3M) | |
Net Income | (291.0M) | (306.6M) | (340.1M) | (2.3B) | (2.8B) | (2.6B) | |
Income Tax Expense | (14K) | (44K) | 12K | 15K | 46K | 15.9K | |
Interest Expense | 11.8M | 10.8M | 9.7M | 2.0M | 5.3M | 4.0M | |
Gross Profit | (8.1M) | (9.9M) | 20.3M | 49.0M | (313K) | (297.4K) | |
Cost Of Revenue | 8.1M | 9.9M | 11.4M | 14.6M | 8.9M | 6.4M | |
Tax Provision | (44K) | 12K | 15K | 46K | 6K | 4.2K | |
Interest Income | 4.7M | 2.4M | 367K | 2.0M | 4.8M | 3.2M | |
Net Interest Income | 4.7M | 2.4M | 367K | 2.0M | 944K | 896.8K |
Atara Biotherapeutics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | 13.6M | 126.1M | (94.3M) | (14.4M) | (67.1M) | (63.7M) | |
Free Cash Flow | (241.4M) | (185.3M) | (231.1M) | (274.6M) | (194.2M) | (203.9M) | |
Other Non Cash Items | 1.0M | 1.5M | 2.0M | (40.2M) | 12.5M | 13.1M | |
Capital Expenditures | 5.7M | 4.5M | 10.6M | 4.2M | 1.2M | 1.2M | |
Net Income | (291.0M) | (306.6M) | (340.1M) | (228.3M) | (276.1M) | (262.3M) | |
End Period Cash Flow | 75.7M | 201.8M | 107.5M | 93.1M | 26.0M | 24.7M | |
Depreciation | 7.1M | 8.3M | 9.3M | 5.7M | 4.8M | 4.0M | |
Change To Netincome | 52.7M | 51.5M | 57.6M | 3.6M | 4.1M | 3.9M | |
Investments | 66.0M | (116.2M) | 32.8M | 112.4M | 165.1M | 173.4M | |
Net Borrowings | (486K) | (389K) | (254K) | 30.1M | 34.6M | 36.3M |
Atara Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Atara Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Atara Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atara Biotherapeutics competition to find correlations between indicators driving Atara Biotherapeutics's intrinsic value. More Info.Atara Biotherapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Atara Biotherapeutics' Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Atara Biotherapeutics' earnings, one of the primary drivers of an investment's value.Atara Biotherapeutics Systematic Risk
Atara Biotherapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atara Biotherapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Atara Biotherapeutics correlated with the market. If Beta is less than 0 Atara Biotherapeutics generally moves in the opposite direction as compared to the market. If Atara Biotherapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atara Biotherapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atara Biotherapeutics is generally in the same direction as the market. If Beta > 1 Atara Biotherapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Atara Biotherapeutics Thematic Clasifications
Atara Biotherapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Cancer Fighters | View |
Today, most investors in Atara Biotherapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atara Biotherapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Atara Biotherapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Atara Biotherapeutics November 8, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Atara Biotherapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atara Biotherapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atara Biotherapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Atara Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atara Biotherapeutics's daily price indicators and compare them against related drivers.
Downside Deviation | 5.47 | |||
Information Ratio | 0.0711 | |||
Maximum Drawdown | 44.5 | |||
Value At Risk | (10.39) | |||
Potential Upside | 10.5 |
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |